The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on ...

Regeneron will report a decline in revenues this year due to the lack of COVID-19 antibody sales. Growth is set to resume in 2023, driven primarily by Dupixent.

Regeneron saw its sales rise in recent years, led by its Covid-19 multi-antibody therapy, which garnered $6 billion in 2021 sales. However, with the pandemic now behind us, sales declined in 2022.

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period ...

Regeneron CEO says $450 million contract with U.S. secured 300K doses of antibody cocktail The following is a transcript of an interview with Regeneron CEO Leonard Schleifer that aired Sunday ...